India to Canada: Acetylsalicylic Export Trade Route

To import ASA formulations into Canada, the following approvals and registrations are necessary:

• Drug Identification Number (DIN): Each ASA product must obtain a DIN from Health Canada before it can be marketed. The DIN serves as a unique identifier indicating that the product has been evaluated and authorized for sale.

• Drug Establishment Licence (DEL): Importers must hold a valid DEL for the activity of importation. Additionally, the foreign manufacturing site must be listed on the importer's DEL.

• Common Technical Document (CTD/eCTD) Format: Submissions for product approval should be prepared in the CTD or electronic CTD (eCTD) format, encompassing modules such as quality, safety, and efficacy data.

• Timelines and Fees: Approval timelines and associated fees can vary based on the submission type and product specifics.

• Good Manufacturing Practices (GMP) Inspection: Health Canada mandates that foreign manufacturing facilities comply with GMP standards. Indian manufacturers exporting ASA formulations must undergo GMP inspections to ensure compliance with Canadian regulations.

Indian exporters of ASA formulations must adhere to the following GMP standards to supply the Canadian market:

• GMP Certification: Manufacturing facilities must comply with GMP requirements as outlined in Part C, Division 2 of the Food and Drug Regulations.

• Health Canada Inspections: Health Canada conducts inspections of foreign manufacturing sites to verify GMP compliance. Indian facilities exporting to Canada are subject to these inspections.

• Recent Regulatory Actions: As of March 2026, there have been no publicly disclosed regulatory actions by Health Canada against Indian pharmaceutical companies exporting ASA formulations.

Several regulatory developments between 2024 and 2026 have impacted Indian pharmaceutical exports to Canada:

• Revised GMP Rules in India: In January 2024, India's Ministry of Health revised its GMP regulations to align more closely with global standards, including those of the World Health Organization. This revision aims to enhance the quality of pharmaceutical products intended for export.

• Regulatory Symposium: A joint symposium involving the FDA, MHRA, and Health Canada is scheduled for June 2-4, 2026, in Ottawa. The event will focus on regulatory perspectives in good clinical practice, bioequivalence, and pharmacovigilance, potentially influencing future regulatory policies affecting pharmaceutical imports.

Staying informed about these developments is crucial for Indian exporters to ensure compliance with evolving regulatory requirements in the Canadian market.

In 2024, Canada imported a total of X tons of o-acetylsalicylic acid, its salts, and esters, marking an increase from previous years. Despite this growth, the overall trend since 2014 indicates a decline in import volumes. The primary supplier in 2024 was France, accounting for a significant share of the imports, followed by China. (indexbox.io)

The demand for acetylsalicylic formulations in Canada is driven by several factors:

• Aging Population: An increasing number of elderly individuals contributes to higher consumption of medications for chronic conditions.

• Healthcare Spending: Canada's healthcare expenditure supports the availability and accessibility of pharmaceutical products.

• Universal Health Coverage: The country's healthcare system ensures that residents have access to necessary medications, including acetylsalicylic formulations.

While specific data on domestic production versus imports of acetylsalicylic formulations is not readily available, the import figures suggest a reliance on international suppliers to meet domestic demand.

Pharmaceutical products under HS code 30049099, including acetylsalicylic formulations, are imported into Canada with a 0% MFN duty rate. This favorable tariff structure facilitates the importation of these products. Additionally, Canada has free trade agreements (FTAs) with various countries, which may further influence the import dynamics of pharmaceutical products. However, specific details regarding FTAs affecting acetylsalicylic formulations are not specified.

In 2024, France was the leading supplier of o-acetylsalicylic acid to Canada, with China also contributing to the import volumes. (indexbox.io) India's share in Canada's total acetylsalicylic imports is not explicitly detailed, but the available data indicates that other countries, particularly France and China, hold significant positions in the market.

Pricing comparisons between Indian suppliers and competitors such as China and European manufacturers are not provided in the available data. However, India's pharmaceutical industry is known for its cost-effective production capabilities, which may offer competitive pricing advantages in the global market.

India has solidified its position as a global leader in the production of generic pharmaceuticals, supplying approximately 20% of the world's generic drugs. This dominance is underpinned by a robust manufacturing infrastructure, including 752 FDA-approved facilities and 2,050 WHO-GMP-certified plants as of 2024. These certifications ensure that Indian manufacturers adhere to stringent international quality standards, making them reliable partners for global pharmaceutical needs.

The country's cost-effective production methods are a significant advantage. India's pharmaceutical industry has achieved a 24% increase in labor productivity between 2014 and 2023, coupled with a 40% improvement in on-time-in-full delivery rates. These efficiencies translate into competitive pricing for finished dosage forms, including tablets and capsules containing acetylsalicylic acid. Additionally, the widespread adoption of AI and automation has led to a 99.9% right-first-time performance at leading manufacturing sites, ensuring consistent product quality.

The combination of extensive manufacturing capacity, cost efficiency, and stringent quality control positions India as a preferred source for acetylsalicylic acid formulations globally.

When evaluating acetylsalicylic acid formulations, India's offerings are competitively priced and meet high-quality standards. In Q3 2025, the average price of acetylsalicylic acid in India was $2,850 per metric ton, closely aligning with the U.S. price of $2,865 per metric ton. In contrast, China's price stood at $2,480 per metric ton, and Germany's at $2,342 per metric ton. While China's lower pricing may seem attractive, concerns about quality and regulatory compliance persist. India's pharmaceutical sector has demonstrated a 50% reduction in FDA Official Action Indicated outcomes over the past decade, reflecting a strong commitment to quality and regulatory adherence.

European Union manufacturers, particularly in Germany, are known for high-quality pharmaceutical products but often come with higher costs due to stringent regulatory environments and higher production expenses. For Canadian buyers, sourcing from India offers a balanced approach, combining cost-effectiveness with assured quality and regulatory compliance.

India's pharmaceutical industry has made significant investments in infrastructure and operations to enhance supply reliability. The country now operates 752 FDA-approved and 2,050 WHO-GMP-certified manufacturing plants, surpassing the United States in the number of FDA-registered generic manufacturing sites. This extensive capacity ensures a steady supply of acetylsalicylic acid formulations.

The adoption of advanced technologies, including AI and automation, has led to a 99.9% right-first-time performance at leading sites, minimizing production errors and ensuring consistent product quality. Additionally, the industry has achieved a 40% increase in on-time-in-full delivery rates, indicating a strong commitment to meeting delivery schedules.

While no significant supply disruptions have been reported recently, it is advisable for buyers to maintain open communication with suppliers to stay informed about any potential issues.

For Canadian buyers looking to source acetylsalicylic acid formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Minimum Order Quantities (MOQs): Be aware that MOQs can vary among suppliers. Establish clear agreements on order sizes to align with your inventory requirements and supplier capabilities.

• Payment Terms: Standard payment terms in India-Canada pharmaceutical trade often include letters of credit or advance payments. Negotiate terms that balance financial security with cash flow considerations.

• Supplier Qualification Process: Implement a thorough qualification process, including audits of manufacturing facilities, verification of regulatory certifications, and assessment of quality control systems to ensure compliance with Canadian standards.

• Regulatory Compliance: Ensure that the selected suppliers have a strong track record of regulatory compliance, as evidenced by FDA and WHO-GMP certifications, to guarantee product quality and safety.

By adopting these strategies, Canadian buyers can establish a reliable and efficient supply chain for acetylsalicylic acid formulations from India.

By adhering to this comprehensive approach, Canadian companies can effectively qualify Indian suppliers of acetylsalicylic acid formulations, ensuring product quality, regulatory compliance, and patient safety.